文献速递胃肠动力与功能性疾病

5-HT4受体激动剂felcisetrag对胃轻瘫患者肠道传输影响的随机研究

Randomised study: effects of the 5-HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.
PubMed 文献 · Aliment Pharmacol Ther · 2021-03-12

这项单中心安慰剂对照研究纳入36例胃排空延迟的胃轻瘫患者,随机接受felcisetrag 0.1mg、0.3mg、1.0mg或安慰剂静脉输注3天。结果显示felcisetrag显著加速胃排空T1/2、6小时结肠充盈和小肠传输时间,且耐受性良好。

要点

  • felcisetrag显著加速胃轻瘫患者的胃排空、小肠和结肠传输。
  • 药代动力学呈剂量比例关系,安全性和耐受性良好。
  • 需进一步评估felcisetrag短期治疗胃肠动力障碍的价值。

核心结论

  • 静脉felcisetrag显著加速胃轻瘫患者的胃、小肠和结肠传输,应进一步评估其短期治疗胃肠动力障碍的作用。

研究设计与样本

  • 单中心、安慰剂对照研究,36例胃轻瘫患者随机接受安慰剂或felcisetrag 0.1mg、0.3mg、1.0mg静脉输注每日一次共3天。
  • 基线时完成4小时99mTc-鸡蛋餐胃排空试验,第2天输注后48小时内测量胃、小肠和结肠传输。
  • 主要终点为胃排空T1/2,统计分析采用基线参数作为协变量的ANCOVA。

主要发现

  • 与安慰剂相比,felcisetrag显著加速胃排空T1/2、6小时结肠充盈和10%小肠传输时间(总体P < 0.01;三个剂量分别Bonferroni校正P < 0.05)。
  • 所有剂量均显著加速升结肠排空T1/2。
  • 0.1mg和0.3mg felcisetrag相比安慰剂显著加速48小时结肠传输。
  • 药代动力学结果呈剂量比例关系。
  • felcisetrag耐受性良好,临床实验室、生命体征或心电图无临床显著发现。

临床怎么用

  • felcisetrag可能用于短期改善胃轻瘫患者的胃和小肠动力,但需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastroparesis is defined by delayed gastric emptying with associated symptoms in the absence of mechanical obstruction. AIM: To evaluate pharmacokinetics and pharmacodynamics of felcisetrag, a highly selective 5-HT4 receptor agonist, on total gut transit in patients with documented delayed gastric emptying of solids. METHODS: Single-centre, placebo-controlled study of 36 participants receiving placebo, 0.1mg, 0.3mg or 1.0mg of felcisetrag I.V. infusion, daily, for 3 days. At baseline, each participant completed a 4h, 99m Tc-egg meal (300 kcal, 30% fat) gastric emptying test. Following infusion (Day 2), gastric, small bowel and colonic transit of solids were measured over 48h (same meal plus 111 In-charcoal delivered in methacrylate-coated capsule). Samples were collected for pharmacokinetics. The primary endpoint was gastric emptying T1/2 . Statistical analysis used baseline parameters as covariates (ANCOVA). RESULTS: Patients (22 idiopathic, 14 diabetic gastroparesis) were randomised to felcisetrag (0.1 mg, n = 10; 0.3 mg, n = 9; 1.0 mg, n = 7) or placebo (n = 10). Compared to placebo, felcisetrag significantly accelerated gastric emptying T1/2 , colonic filling at 6h, and 10% small bowel transit time (overall P < 0.01; all three doses individually Bonferroni corrected P < 0.05) for all three measurements. Ascending colon emptying (T1/2 ) was significantly accelerated (all doses), and colonic transit at 48 hours was accelerated with 0.1 mg and 0.3 mg felcisetrag compared to placebo. Pharmacokinetic results were dose proportional. Felcisetrag was well tolerated with no clinically significant findings from clinical laboratory, vital signs or ECG. CONCLUSION: I.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chedid V, Brandler J, Arndt K, et al. Randomised study: effects of the 5-HT4 receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis. Aliment Pharmacol Ther. 2021. PMID: 33711180. doi:10.1111/apt.16304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。